Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individual albuminuria lowering response to dapagliflozin in a decentralized setting
2020-004929-23Phase 4Active
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dapagliflozin in type 2 diabetes mellitus (T2DM) and albuminuria, sponsored by University Medical Center Groningen. Primary endpoints: Feasibility and user-friendliness of remote data collection and Patient experience with remote data collection. Started Dec 2020; status: active.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)albuminuria
Beyond the preview
Go deeper on 2020-004929-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004929-23.